ADD2 | Adducin 2 (beta) | Cytoskeleton related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/9796/24747_B_1_7_rna_selected_60x60.jpg) | Group enriched |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | ![](/images/1198/2772_A_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
CA1 | Carbonic anhydrase I | Enzymes FDA approved drug targets Plasma proteins
| | ![](/images_static/na_center.gif) | | ![](/images/6558/22094_B_9_1_rna_selected_60x60.jpg) | Group enriched |
CCR7 | Chemokine (C-C motif) receptor 7 | Cancer-related genes CD markers G-protein coupled receptors Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/3796/11202_A_9_6_rna_selected_60x60.jpg) | Group enriched |
CD247 | CD247 molecule | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/8750/27531_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
CD27 | CD27 molecule | Cancer-related genes CD markers Disease related genes Plasma proteins Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2420/6095_A_9_7_rna_selected_60x60.jpg) | Tissue enhanced |
CD3E | CD3e molecule, epsilon (CD3-TCR complex) | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/43955/119468_A_8_3_rna_selected_60x60.jpg) | Tissue enhanced |
CD48 | CD48 molecule | CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2497/6307_A_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
CD6 | CD6 molecule | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images/2489/if_selected_60x60.jpg) | | ![](/images/2489/6143_B_7_2_rna_selected_60x60.jpg) | Tissue enhanced |
CD69 | CD69 molecule | CD markers Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2503/6465_A_8_7_rna_selected_60x60.jpg) | Tissue enhanced |
CEACAM5 | Carcinoembryonic antigen-related cell adhesion molecule 5 | Cancer-related genes CD markers Plasma proteins Predicted membrane proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/21/18_B_7_1_rna_selected_60x60.jpg) | Group enriched |
CTSG | Cathepsin G | Enzymes Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/47737/123206_B_8_8_rna_selected_60x60.jpg) | Tissue enriched |
FCER2 | Fc fragment of IgE, low affinity II, receptor for (CD23) | Cancer-related genes CD markers Predicted membrane proteins
| | ![](/images/8928/if_selected_60x60.jpg) | | ![](/images/2624/6433_A_9_8_rna_selected_60x60.jpg) | Group enriched |
FCN1 | Ficolin (collagen/fibrinogen domain containing) 1 | Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/685/1469_B_1_5_rna_selected_60x60.jpg) | Group enriched |
IKZF1 | IKAROS family zinc finger 1 (Ikaros) | Cancer-related genes Disease related genes Predicted membrane proteins Transcription factors
| | ![](/images_static/na_center.gif) | | ![](/images/9247/32859_A_9_3_rna_selected_60x60.jpg) | Tissue enhanced |
IRF8 | Interferon regulatory factor 8 | Disease related genes Plasma proteins Transcription factors
| | | | ![](/images/2267/7977_A_1_5_rna_selected_60x60.jpg) | Tissue enhanced |
LAG3 | Lymphocyte-activation gene 3 | CD markers Predicted membrane proteins Predicted secreted proteins
| | ![](/images/2301/if_selected_60x60.jpg) | | ![](/images/13967/30400_B_8_1_rna_selected_60x60.jpg) | Tissue enhanced |
LCK | Lymphocyte-specific protein tyrosine kinase | Cancer-related genes Disease related genes Enzymes FDA approved drug targets
| | ![](/images/3494/if_selected_60x60.jpg) | | ![](/images/3816/10092_B_2_2_rna_selected_60x60.jpg) | Tissue enhanced |
LEF1 | Lymphoid enhancer-binding factor 1 | Plasma proteins Transcription factors
| | ![](/images/2087/if_selected_60x60.jpg) | | ![](/images/2087/7385_B_2_7_rna_selected_60x60.jpg) | Tissue enhanced |
LRMP | Lymphoid-restricted membrane protein | Predicted membrane proteins
| | ![](/images_static/na_center.gif) | | ![](/images/2967/9462_A_7_2_rna_selected_60x60.jpg) | Tissue enhanced |
MPO | Myeloperoxidase | Cancer-related genes Candidate cardiovascular disease genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/21147/146570_B_7_6_rna_selected_60x60.jpg) | Tissue enriched |
MS4A1 | Membrane-spanning 4-domains, subfamily A, member 1 | CD markers Disease related genes FDA approved drug targets Predicted membrane proteins Transporters
| | ![](/images_static/na_center.gif) | | ![](/images/14341/39080_B_8_5_rna_selected_60x60.jpg) | Group enriched |
NCF1 | Neutrophil cytosolic factor 1 | Disease related genes
| | ![](/images_static/na_center.gif) | | ![](/images/47836/129864_B_8_6_rna_selected_60x60.jpg) | Tissue enhanced |
PLEK | Pleckstrin | Plasma proteins
| | ![](/images_static/na_center.gif) | | ![](/images/31838/68854_B_8_5_rna_selected_60x60.jpg) | Tissue enhanced |
POU2F2 | POU class 2 homeobox 2 | Cancer-related genes Transcription factors
| | ![](/images_static/na_center.gif) | | ![](/images/2513/6474_A_9_5_rna_selected_60x60.jpg) | Tissue enhanced |
PPBP | Pro-platelet basic protein (chemokine (C-X-C motif) ligand 7) | Plasma proteins Predicted secreted proteins
| | ![](/images_static/na_center.gif) | | ![](/images/8354/21865_B_7_4_rna_selected_60x60.jpg) | Tissue enriched |
RASAL3 | RAS protein activator like 3 | RAS pathway related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/43417/119259_B_9_1_rna_selected_60x60.jpg) | Tissue enhanced |
RIPK2 | Receptor-interacting serine-threonine kinase 2 | Cytoskeleton related proteins Enzymes
| | | | ![](/images/16499/38746_B_9_2_rna_selected_60x60.jpg) | Tissue enhanced |
SASH3 | SAM and SH3 domain containing 3 | | | ![](/images_static/na_center.gif) | | ![](/images/1085/2601_B_7_1_rna_selected_60x60.jpg) | Tissue enhanced |
SNCA | Synuclein, alpha (non A4 component of amyloid precursor) | Cytoskeleton related proteins Disease related genes Plasma proteins Potential drug targets Transporters
| | ![](/images_static/na_center.gif) | | ![](/images/5459/20095_B_6_6_rna_selected_60x60.jpg) | Tissue enhanced |
SPN | Sialophorin | CD markers Predicted membrane proteins
| | ![](/images/2666/if_selected_60x60.jpg) | | ![](/images/55244/134326_A_8_2_rna_selected_60x60.jpg) | Tissue enhanced |
SPTB | Spectrin, beta, erythrocytic | Disease related genes Plasma proteins
| | | | ![](/images/3394/10561_B_7_3_rna_selected_60x60.jpg) | Group enriched |
TCL1A | T-cell leukemia/lymphoma 1A | Cancer-related genes Disease related genes
| | ![](/images_static/na_center.gif) | | ![](/images/16604/37652_B_2_5_rna_selected_60x60.jpg) | Tissue enhanced |
ZAP70 | Zeta-chain (TCR) associated protein kinase 70kDa | Disease related genes Enzymes Plasma proteins Potential drug targets RAS pathway related proteins
| | ![](/images_static/na_center.gif) | | ![](/images/3134/8985_B_7_8_rna_selected_60x60.jpg) | Tissue enhanced |